Acumen Hypotension Prediction Index – EV1000 Clinical Platform vs VX1+

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
Acumen Hypotension Prediction Index – EV1000 Clinical Platform
by Edwards Lifesciences
VS
VX1+
by Volta Medical

AI Verdict

These tools are adjacent rather than direct competitors, as they address distinct clinical problems within the broader cardiology and surgical AI domains. Tool A focuses on predicting and managing systemic hypotension and hemodynamic instability across various critical care and surgical settings. In contrast, Tool B is specifically designed to assist electrophysiologists in real-time identification of abnormal electrograms during cardiac ablation procedures for arrhythmias.

Choose Acumen Hypotension Prediction Index – EV1000 Clinical Platform if…

Choose the Acumen Hypotension Prediction Index – EV1000 Clinical Platform if your primary goal is to proactively prevent and manage intraoperative hypotension. This tool is ideal for anesthesiologists and critical care teams who require early, machine learning-driven alerts (up to 15 minutes in advance) regarding hemodynamic instability, enabling timely interventions to maintain patient blood pressure and reduce adverse events.

View Acumen Hypotension Prediction Index – EV1000 Clinical Platform →

Choose VX1+ if…

Choose VX1+ if you are an electrophysiologist performing cardiac ablation procedures for atrial fibrillation or atrial tachycardia and need real-time, AI-powered assistance in identifying abnormal electrograms. This software is best suited for enhancing the precision and efficiency of ablation by providing clear, color-coded insights into spatio-temporal dispersed electrograms, helping to optimize target selection during complex procedures.

View VX1+ →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Acumen Hypotension Prediction Index – EV1000 Clinical Platform VX1+
Deployment On-premise (integrated with EV1000 clinical platform and HemoSphere advanced monitoring platform) Software, compatible with most multipolar catheters and mapping technologies used in operating rooms or electrophysiology labs.
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Acumen Hypotension Prediction Index – EV1000 Clinical Platform

Tool A integrates seamlessly with the established Edwards Lifesciences HemoSphere Advanced Monitoring Platform, offering a clear HPI score, Smart Alerts, and visual screens for hemodynamic insights. This dedicated platform integration and actionable parameters suggest a highly streamlined and purpose-built user experience. While Tool B also features a simple, color-coded interface and integrates with existing EP systems, Tool A's comprehensive ecosystem likely provides a more cohesive and intuitive workflow for real-time hemodynamic management.

Clinical Value

VX1+

Tool B, VX1+, has demonstrated significant clinical impact in a highly complex and challenging area. The TAILORED-AF trial showed that AI-guided ablation with Volta AF-Xplorer (which VX1+ is part of) resulted in 88% freedom from AF at 12 months, compared to 70% with conventional ablation, representing a substantial improvement in outcomes for persistent atrial fibrillation. While Tool A significantly reduces intraoperative hypotension, Tool B's ability to improve success rates in a procedure with historically high recurrence rates offers a transformative clinical advantage in its specialized field.

Pricing & Value

Tie

Neither Tool A nor Tool B provides publicly available pricing information. Both are specialized, FDA-cleared medical devices, indicating they likely represent significant investments for healthcare institutions. Without transparent pricing details, a direct comparison of their value proposition is not possible.

Enterprise Readiness

Acumen Hypotension Prediction Index – EV1000 Clinical Platform

Tool A benefits from being a product of Edwards Lifesciences, a large and established global medical technology company, explicitly stating HIPAA compliance and offering 24/7 technical support. Its integration with the HemoSphere platform suggests a mature product with robust support infrastructure and comprehensive documentation. Tool B, from a smaller startup, lacks explicit statements regarding HIPAA and BAA, and its support infrastructure is less clearly defined, indicating a potentially lower level of enterprise readiness.

Innovation

VX1+

Both tools are innovative, leveraging AI for real-time clinical decision support. However, Tool B's application of AI to the real-time identification and annotation of complex spatio-temporal dispersed electrograms during cardiac ablation procedures is particularly groundbreaking. This addresses a significant challenge in electrophysiology by standardizing and improving outcomes in a highly operator-dependent procedure.

Support & Docs

Acumen Hypotension Prediction Index – EV1000 Clinical Platform

Edwards Lifesciences, the developer of Tool A, explicitly offers 24/7 technical support and a comprehensive suite of educational resources and documentation for Acumen HPI and its integrated HemoSphere platform. While Volta Medical provides a user manual and contact information for Tool B, it does not detail the same extensive, round-the-clock support or broad educational programs, making Tool A superior in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Acumen Hypotension Prediction Index – EV1000 Clinical Platform VX1+
Tool Name Acumen Hypotension Prediction Index u2013 EV1000 Clinical Platform VX1+
Company Edwards Lifesciences Volta Medical
Primary Function Uses machine learning to predict hypotensive events up to 15 minutes in advance, providing clinicians with insights into hemodynamic instability and potential causes to help reduce intraoperative hypotension. AI-powered software that assists electrophysiologists in real-time identification of abnormal electrograms during cardiac ablation procedures for atrial fibrillation and atrial tachycardia.
Target Specialties Anesthesiology, Critical Care, Emergency Medicine Cardiology
Core AI Capability Machine learning-based algorithm for predicting hypotension up to 15 minutes in advance. AI-driven insights for real-time identification of spatio-temporal dispersed electrograms (DEs) during AF and AT procedures.
Monitoring/Input Method Continuous hemodynamic monitoring via non-invasive (Acumen IQ cuff) and minimally-invasive (Acumen IQ sensor) options. Compatibility with existing 510(k)-cleared catheters and specific data acquisition systems (e.g., Boston Scientific LabSystem Pro, GE HealthCare MacLab CardioLab EP Recording System, Abbott EnSite X 3D mapping system).

Videos

Demos, reviews, and walkthroughs featuring Acumen Hypotension Prediction Index – EV1000 Clinical Platform and VX1+.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Acumen HPI integrates with Edwards Lifesciences HemoSphere Advanced Monitoring Platform, providing continuous hemodynamic data and predictive insights directly within the monitoring environment. This allows clinicians to incorporate real-time HPI scores and Smart Alerts into their decision-making process during procedures or in critical care settings. VX1+ integrates as a software application with existing EP recording and 3D mapping systems, such as Abbott EnSite X or Boston Scientific LabSystem Pro. It provides real-time AI-driven annotations of electrograms directly within the EP lab workflow, assisting electrophysiologists in identifying target areas for ablation.
Acumen HPI has demonstrated high accuracy in predicting hypotension, with a sensitivity of 90% and specificity of 89% at 10 minutes before an event. This predictive capability aims to reduce intraoperative hypotension by providing early insights into hemodynamic instability and potential causes, potentially reducing the duration and severity of hypotensive events. VX1+ assists in real-time identification of spatio-temporal dispersed electrograms (DEs) during AF and AT procedures, with a 'Booster mode' available for increased sensitivity. Studies suggest it can reproduce expert-physician electrogram analysis and facilitate standardization of abnormal electrogram detection, which may lead to improved ablation outcomes.
Acumen HPI is best suited for anesthesiology, critical care, and emergency medicine, focusing on surgical and non-surgical patients receiving advanced hemodynamic monitoring who are at risk of hypotension. It addresses the unmet need for early prediction and proactive management of hypotension to improve patient outcomes. VX1+ is specifically designed for cardiology, particularly electrophysiologists performing cardiac ablation procedures for atrial fibrillation and atrial tachycardia. It addresses the challenge of accurately identifying abnormal electrograms in real-time to enhance ablation efficacy and standardize outcomes.
Acumen HPI presents a HPI score, Smart Alerts, and visual screens like Smart Trend and Relationship View, requiring clinicians to learn the interpretation of these new hemodynamic parameters and insights into preload, afterload, and contractility. VX1+ features a simple user interface with color coding for electrogram dispersion, providing real-time visual cues for abnormal electrograms. The system is designed to allow for a fast learning curve and standardized outcomes across operators.
Edwards Lifesciences offers support for Acumen HPI, including clinical evidence and frequently asked questions. Volta Medical has initiated multi-center clinical trials for VX1+, such as TAILORED-AF and RESTART, which involve numerous sites and operators, suggesting opportunities for peer connection and real-world data. Both companies, being established in the medical device space, are expected to provide ongoing technical and clinical support.
Multi-site rollout of Acumen HPI would require standardization of the Edwards Lifesciences HemoSphere Advanced Monitoring Platform and dedicated Acumen IQ sensors across all sites. Training would focus on consistent interpretation of HPI parameters and integration into existing critical care and OR protocols. For VX1+, multi-site implementation involves ensuring compatibility with existing EP recording and 3D mapping systems at each location. Training would be crucial for electrophysiologists to standardize the interpretation and application of the AI-driven electrogram annotations across different sites, with studies indicating it allows for robust center-to-center standardization.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform
AISAP Cardio vs Rapid Enterprise Platform
AngioWaveNet vs Rapid Enterprise Platform
CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Acumen Hypotension Prediction Index – EV1000 Clinical Platform or VX1+

AI Tool Finder
AI-powered search. Results may not be comprehensive.